- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001064
A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells > 350 Cells/mm3
To define the safety and efficacy of sibling-supplied, HIV antigen-pulsed dendritic cells in increasing the immune response in HIV-infected patients.
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic cells from an HIV-negative sibling may enable the affected sibling's immune system to recognize foreign particles more readily and increase immune response against the virus.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dendritic cells are a type of white blood cell used by the body to fight infection. They are instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic cells from an HIV-negative sibling may enable the affected sibling's immune system to recognize foreign particles more readily and increase immune response against the virus.
Dendritic cells from an HIV-negative sibling are obtained and treated with various viral proteins (HIV vaccines) or immunomodulators. The treated dendritic cells are infused into the HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple occasions, and patients are followed every 2-4 weeks during the study. Patients are screened over 3 months prior to study entry.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 943055107
- Stanford Univ School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Patients must have:
- HLA A2+.
- Same cell type as donor sibling.
- CD4 count > 350 cells/mm3.
- HIV asymptomatic status.
- No HIV antivirals during study.
- Normal labs and chest x-ray.
Donor siblings must have:
- HLA A2+.
- HIV negativity.
- Ability to donate cells on multiple occasions.
- Negative status for hepatitis B and C.
Exclusion Criteria
Concurrent Medication:
Excluded:
- Antiviral therapy (unless CD4 count declines to < 350 cells/mm3).
Prior Medication:
Excluded:
- Antiviral therapy within 90 days prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Study record dates
Study Major Dates
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPIRAT 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Allogenic Dendritic Cells
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Xuzhou Medical UniversityRecruitingB-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic LeukemiaChina
-
H. Lee Moffitt Cancer Center and Research InstituteThe Shulas' FoundationRecruitingTriple Negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Sri Sai College of Dental Surgery and Research...UnknownEdentulous Alveolar RidgeIndia
-
Fundació Sant Joan de DéuInstitut d'Investigacions Biomèdiques August Pi i SunyerUnknownDiffuse Intrinsic Pontine GliomaSpain
-
Fundacion Clinic per a la Recerca BiomédicaTerminatedCrohn's DiseaseSpain
-
University of PittsburghCompletedType 1 DiabetesUnited States
-
Ever Supreme Bio Technology Co., Ltd.Recruiting
-
Statens Serum InstitutRigshospitalet, Denmark; Hvidovre University HospitalCompleted